James Xue
薛群
James Xue is the founder, chairman, and CEO of CANbridge Pharmaceuticals, a biopharmaceutical company focused on rare diseases . Under his leadership, the company secured approval for velaglucerase alfa for injection (brand name: Gerining), a first-in-class enzyme replacement therapy for Type I and Type III Gaucher disease in China, which he described as a milestone for CANbridge's global pipeline . Elsewhere's corpus does not cover his personal background or career prior to CANbridge.
AI-generated — may contain errors, please verify.
Coverage
Qiming Weekly | Top 10 News from Qiming Venture Partners Portfolio Companies Vol.25, 2026.8.11
Following Qiming Venture Partners' portfolio companies as they hit milestone moments.
Qiming Weekly | Qiming Venture Partners Portfolio News and Updates Vol. 30, 2025
Celebrating milestone moments with Qiming Venture Partners' portfolio companies
Qiming Star | CANbridge Pharma's velaglucerase alfa for injection (brand name: Gerining), a first-in-class drug for Type I and Type III Gaucher disease, approved for market launch in China
Gorenicin is not only the third rare disease treatment drug launched by CANbridge after Hymricin and Myrbetriq, but also the first self-developed product poised for commercialization.
